Results 31 to 40 of about 15,630 (215)

Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study

Frontiers in Oncology, 2023
BackgroundBevacizumab has played an important role in the systemic treatment of patients with advanced non-small-cell lung cancer (NSCLC) without gene mutation.
Zhiting Zhao, Luqing Zhao, Guohao Xia, Jianwei Lu, Jianwei Lu, Bo Shen, Guoren Zhou, Fenglei Wu, Xiao Hu, Jifeng Feng, Shaorong Yu, Shaorong Yu   +11 more
doaj   +1 more source

Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars

Терапевтический архив, 2021
Aim. To define the frequency of adverse events and loss of the response in patients with ulcerative colitis (UC) and Crohns disease (CD), treated with original medicine infliximab (IFX) Remicaide and its biosimilars. Materials and methods. We included
O. V. Knyazev, M. Yu. Zvyaglova, A. V. Kagramanova, I. A. Li, E. A. Sabelnikova, A. A. Lishchinskaya, D. S. Kulakov, A. I. Parfenov   +7 more
doaj   +1 more source

What do oncologists need to know about biosimilar products?

Chinese Journal of Cancer, 2016
Many biologic products have improved the outcomes of cancer patients, but the costs can substantially burden healthcare systems. Biosimilar products can potentially reduce drug costs and increase patient access to beneficial treatments.
Linda K. S. Leung, Kevin Mok, Calvin Liu, Stephen L. Chan   +3 more
doaj   +1 more source

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices

ACR Open Rheumatology, 2020
Objective It is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility.
Nick Bansback, Jeffrey R. Curtis, Jie Huang, Zeling He, Michael Evans, Tracy Johansson, Kaleb Michaud, Gabriela Schmajuk, Katherine P. Liao   +8 more
doaj   +1 more source

Characterization of Full‐Length Antibody Complexes Through HDX‐Mass Spectrometry Coupled With NMR Spectroscopy: New Insight Into Avelumab/PD‐L1 Interaction

Angewandte Chemie, EarlyView.
Combining HDX‐MS and NMR enables the mapping of epitopes and paratopes in full‐length antibody complexes, revealing transient interactions and potential artifacts. ABSTRACT Recombinant biomacromolecules have significantly transformed pharmaceuticals, in particular monoclonal antibodies (mAbs) that target key areas in oncology, immunology, inflammation,
Francesca Sacco, Fabio Baroni, Angela Capolupo, Sofia Petrocchi, Jonathan Zöller, Linda Cerofolini, Pasquale Russomanno, Rebecca Calamandrei, Bianca Susini, Siyu Lin, Fabio D'Amici, Enrico Ravera, Julian Langer, Marco Fragai   +13 more
wiley   +2 more sources

Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

Angewandte Chemie, EarlyView.
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma, Komal Sharma, Anku Sharma, Kamya Rao, Rahul Jain, Brett VanVeller   +5 more
wiley   +2 more sources

Key drivers for market penetration of biosimilars in Europe

Journal of Market Access & Health Policy, 2017
Background & Objectives: Potential drivers and barriers of biosimilar uptake were mainly analysed through qualitative approaches. The study objective was to conduct a quantitative analysis and identify drivers of biosimilar uptake of all available ...
Cécile Rémuzat, Julie Dorey, Olivier Cristeau, Dan Ionescu, Guerric Radière, Mondher Toumi   +5 more
doaj   +1 more source

Financial Analysis of Biosimilar Development Candidates: A Case Study on the US Biosimilar Business

, 2016
This case study investigates the US biosimilar business and the approach that should be implemented when financially analyzing biosimilar development candidates.
Gutierrez, Bryan J.
core   +6 more sources

Ligand‐Directed Molecular Beacons as Turn‐On Fluorescent Probes for Sensing Cell‐Surface Receptor‐Ligand Interactions

Angewandte Chemie, EarlyView.
Multivalent, ligand‐directed molecular beacons enable fluorescence turn‐on detection of cell‐surface receptors in living cells. The probes strongly engage closely spaced membrane receptors and exhibit conformation‐dependent fluorescence enhancement at the cell surface, enabling wash‐free receptor imaging, inhibitor screening, and functional evaluation ...
Noa Oppenheimer‐Low, Denis Shpalter, Suraj Toraskar, Martín López‐Vidal, Ziv Porat, Inna Goliand, Ekaterina Petrovich‐Kopitman, Noga Kozer, Haim Michael Barr, Alla H. Falkovich, Leila Motiei, David Margulies   +11 more
wiley   +2 more sources

Biosimilar Drugs for Therapy of Immune-Mediated Diseases

, 2018
In recent years, biological therapy has been widely used for the treatment of immunemediated diseases in rheumatology, hematology, gastroenterology, etc.
Tsvetelina Velikova
core   +1 more source